Toxicity of voriconazole on corneal endothelial cells in an animal model

British Journal of Ophthalmology

Volumn 96, Issue 6, 2012, Pages 905-908

  Han, Sang Beom ^a,b   Yang, Hee Kyung ^a,b   Hyon, Joon Young ^a,b   Shin, Young Joo ^c   Wee, Won Ryang ^a  

^a Seoul National University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Hallym University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ASSAY; CELL COUNT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORNEA THICKNESS; CORNEAL ENDOTHELIAL CELL LOSS; NONHUMAN; PRIORITY JOURNAL; RABBIT; SCANNING ELECTRON MICROSCOPY;

ANIMALS; ANTERIOR CHAMBER; ANTIFUNGAL AGENTS; CELL COUNT; CORNEAL ENDOTHELIAL CELL LOSS; ENDOTHELIUM, CORNEAL; INJECTIONS, INTRAOCULAR; MICROSCOPY, ELECTRON, SCANNING; MODELS, ANIMAL; PYRIMIDINES; RABBITS; TRIAZOLES;

EID: 84862784597     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2011-301129     Document Type: Article

References (25)

1. Gao H, Pennesi ME, Shah K, et al. Intravitreal voriconazole: an electroretinographic and histopathologic study. Arch Ophthalmol 2004;122:1687-92. (Pubitemid 39473415)
2. Warrilow AG, Martel CM, Parker JE, et al. Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob Agents Chemother 2010;54:4235-45.
3. Shen YC, Wang MY, Wang CY, et al. Clearance of intravitreal voriconazole. Invest Ophthalmol Vis Sci 2007;48:2238-41.
4. Kramer M, Kramer MR, Blau H, et al. Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis. Ophthalmology 2006;113:1184-6. (Pubitemid 43947229)
5. Lin RC, Sanduja N, Hariprasad SM. Successful treatment of postoperative fungal endophthalmitis using intravitreal and intracameral voriconazole. J Ocul Pharmacol Ther 2008;24:245-8. (Pubitemid 351450477)
6. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122-31. (Pubitemid 36549632)
7. Cho KS, Lee EH, Choi JS, et al. Reactive oxygen species-induced apoptosis and necrosis in bovine corneal endothelial cells. Invest Ophthalmol Vis Sci 1999;40:911-19. (Pubitemid 29153257)
8. Sen P, Gopal L, Sen PR. Intravitreal voriconazole for drug-resistant fungal endophthalmitis: case series. Retina 2006;26:935-9. (Pubitemid 44547449)
9. Reis A, Sundmacher R, Tintelnot K, et al. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol 2000;84:932-3. (Pubitemid 30599111)
10. Al-Badriyeh D, Leung L, Davies GE, et al. Successful salvage treatment of Scedosporium apiospermum keratitis with topical voriconazole after failure of natamycin. Ann Pharmacother 2009;3:1139-42.
11. Shen YC, Wang CY, Tsai HY, et al. Intracameral voriconazole injection in the treatment of fungal endophthalmitis resulting from keratitis. Am J Ophthalmol 2010;149:916-21.
12. Vemulakonda GA, Hariprasad SM, Mieler WF, et al. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch Ophthalmol 2008;126:18-22.
13. Thiel MA, Zinkernagel AS, Burhenne J, et al. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother 2007;51:239-44. (Pubitemid 46047712)
14. Kernt M, Kampik A. Intracameral voriconazole: in vitro safety for human ocular cells Toxicology 2009;258:84-93.
15. Han SB, Shin YJ, Hyon JY, et al. Cytotoxicity of voriconazole on cultured human corneal endothelial cells. Antimicrob Agents Chemother 2011;10:4519-23.
16. Taylor MJ, Hunt CJ. Dual staining of corneal endothelium with trypan blue and alizarin red S: importance of pH for the dye-lake reaction. Br J Ophthalmol 1981;65:815-19. (Pubitemid 12221905)
17. Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004;122:42-7. (Pubitemid 38063603)
18. Johnson E, Espinel-Ingroff A, Szekely A, et al. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies. Int J Antimicrob Agents 2008;32:511-14.
19. Yilmaz S, Ture M, Maden A. Efficacy of intracameral amphotericin B injection in the management of refractory keratomycosis and endophthalmitis Cornea 2007;26:398-402. (Pubitemid 46684377)
20. den Hollander JG, van Arkel C, Rijnders BJ, et al. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. J Antimicrob Chemother 2006;57:1248-50. (Pubitemid 44644436)
21. Levin MD, den Hollander JG, van der Holt B, et al. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J Antimicrob Chemother 2007;60:1104-7. (Pubitemid 47617761)
22. Lazarus HM, Blumer JL, Yanovich S, et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002;42:395-402. (Pubitemid 34259773)
23. Shen YC, Wang MY, Wang CY, et al. Pharmacokinetics of intracameral voriconazole injection. Antimicrob Agents Chemother 2009;53:2156-7.
24. Olsen EG, Davanger M. The healing of rabbit corneal endothelium. Acta Ophthalmol (Copenh) 1984;62:796-807. (Pubitemid 14006326)
25. Holley GP, Alam A, Kiri A, et al. Effect of indocyanine green intraocular stain on human and rabbit corneal endothelial structure and viability. An in vitro study. J Cataract Refract Surg 2002;28:1027-33. (Pubitemid 34586995)